Indian Pharma Major Ranbaxy had got into trouble when US Food and Drug Administration's ban on 30 of its generic medicines due to poor production standards in two of its manufacturing facilities in India. Days after this ban Ranbaxy has got into more trouble when canada's drug regulator “Health Canada” has now issued a notice that they are going to be doubly cautious about the company's drugs that are being marketed in canada. Incidentally Ranbaxy Canada is being ranked as the ninth largest pharma company in canada by virtue of its sales volume.
Close to the actions of these two countries other countries like Germany, UK and Newzealand have also initiated their Drug regulators to check on the production standards of the company's two manufacturing facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh, India.
It is now upto the company to come clean on the quality issues on the two controversial plants in India as sales volume close to $1.6 Billion is at stake for the pharma major in the markets of US, UK, Europe and North America.
Close to the actions of these two countries other countries like Germany, UK and Newzealand have also initiated their Drug regulators to check on the production standards of the company's two manufacturing facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh, India.
It is now upto the company to come clean on the quality issues on the two controversial plants in India as sales volume close to $1.6 Billion is at stake for the pharma major in the markets of US, UK, Europe and North America.
Comments
Post a Comment